제13회 대한다발성경화증학회 심포지움
일시: 2017-08-19 장소: 서울 쉐라톤 신도림 디큐브시티호텔 6층 그랜드볼룸1. Multiple sclerosis (MS)
석흥열(계명의대)2. Neuromyelitis optica (NMO)
이혜림(고려의대)3. Neurogenic bladder: Botox treatmen
이규성(성균관의대, 비뇨기과)4. Overview: MOA of new drugs
조중양(인제의대)5. Oral drug
박민수(영남의대)6. Natalizumab
신현준(국립암센터)7. Alemtuzumab
임영민(울산의대)8. Principle-based approach: Academic view
민주홍(성균관의대)9. Real-practice-based approach: Coverage of NHI
오지영(건국의대)10. Kim, S.-H., J.-W. Hyun, et al. (2017). "Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders." Mult Scler: 1352458516687403.
김수현(국립암센터)11. Seok, J. M., H.-J. Cho, et al. (2017). "Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea." Mult Scler: 1352458516685416
석진명(순천향의대)12. Kim, S.-M., et al. (2016). "Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G." Mult Scler: 1352458516674366.
김성민(서울의대)13. Jeong IH, Kim HJ, Kim NH, Jeong KS, Park CY (2016) Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder J Neurol 2016 Jul;263(7):1343-8.
김남희(동국의대)